WO2023073082 - CCR6 RECEPTOR MODULATORS
National phase entry:
Publication Number
WO/2023/073082
Publication Date
04.05.2023
International Application No.
PCT/EP2022/080045
International Filing Date
27.10.2022
Title **
[English]
CCR6 RECEPTOR MODULATORS
[French]
MODULATEURS DU RÉCEPTEUR CCR6
Applicants **
IDORSIA PHARMACEUTICALS LTD
Hegenheimermattweg 91
4123 Allschwil, CH
Inventors
ALLEMANN, Oliver
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
HUBLER, Francis
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
MEYER, Emmanuel
c/o Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil, CH
Priority Data
PCT/EP2021/080016
28.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1350 | |
| EPO | Filing, Examination | 5222 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5710 |
Total: 13448 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory/autoimmune diseases/disorders and cancer.[French]
La présente invention concerne des composés de formule (I), leur synthèse et leur utilisation en tant que modulateurs du récepteur CCR6 destinés à prévenir ou traiter, par exemple, des maladies/troubles inflammatoires/auto-immuns et le cancer.